Efficacy of carboplatin-taxane combinations in the management of castration-resistant prostate cancer: A pooled analysis of seven prospective clinical trials

Annals of Oncology

Volumn 21, Issue 2, 2010, Pages 312-318

  Regan, M M ^a   O'Donnell, E K ^b   Kelly, W K ^c   Halabi, S ^d   Berry, W ^e,f   Urakami, S ^g   Kikuno, N ^g   Oh, W K ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c YALE UNIVERSITY   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e Developmental Therapeutics Committee and Co Chair of the Genitourinary Committee   (United States)

^f Cancer Centers of North Carolina   (United States)

^g SHIMANE UNIVERSITY FACULTY OF MEDICINE   (Japan)

Author keywords

Carboplatin; Estramustine; Prostate cancer; Taxanes

Indexed keywords

CARBOPLATIN; DOCETAXEL; ESTRAMUSTINE; PACLITAXEL; PROSTATE SPECIFIC ANTIGEN; TAXANE DERIVATIVE; ANTINEOPLASTIC AGENT; BRIDGED COMPOUND; TAXANE; TAXOID;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; BONE METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DISEASE ASSOCIATION; DIZZINESS; DRUG EFFICACY; DRUG RESPONSE; DYSPNEA; EDEMA; FATIGUE; GASTROINTESTINAL DISEASE; HEART ARRHYTHMIA; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEMATOLOGIC DISEASE; HUMAN; HYPERGLYCEMIA; HYPOPHOSPHATEMIA; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PLEURA EFFUSION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK BENEFIT ANALYSIS; SIDE EFFECT; SURVIVAL TIME; SYNCOPE; THROMBOCYTOPENIA; THROMBOEMBOLISM; THROMBOTIC THROMBOCYTOPENIC PURPURA; VOMITING; CASTRATION; META ANALYSIS; MIDDLE AGED; MORTALITY; PROSTATE TUMOR; STATISTICS; TREATMENT FAILURE; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRIDGED COMPOUNDS; CARBOPLATIN; CASTRATION; CLINICAL TRIALS AS TOPIC; HUMANS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; TAXOIDS; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 77951927865     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdp308     Document Type: Article

References (26)

1. Jemal A, Murray T, Samuels A et al. Cancer statistics, 2003. CA Cancer J Clin 2003; 53: 5-26.
2. De La Taille A, Vacherot F, Salomon L et al. Hormone-refractory prostate cancer: a multi-step and multi-event process. Prostate Cancer Prostatic Dis 2001; 4: 204-212.
3. Petrylak DP, Tangen CM, Hussain MH et al. Docetaxel and estramustine compared to mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351: 1513-1520.
4. Tannock IF, de Wit R, Berry WR et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 1502-1512.
5. Yagoda A, Watson RC, Natale RB et al. A critical analysis of response criteria in patients with prostatic cancer treated with cis-diamminedichloride platinum II. Cancer 1979; 44: 1553-1562.
6. Merrin CE. Treatment of genitourinary tumours with cisdichlorodiammineplatinum(II): experience in 250 patients. Cancer Treat Rep 1979; 63: 1579-1584.
7. Moore MR, Troner MB, DeSimone P et al. Phase II evaluation of weekly cisplatin in metastatic hormone-resistant prostate cancer: a Southeastern Cancer Study Group Trial. Cancer Treat Rep 1986; 70: 541-542.
8. Wagstaff AJ, Ward A, Benfield P et al. Carboplatin. A preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the treatment of cancer. Drugs 1989; 37: 162-190.
9. Miglietta L, Cannobbio L, Boccardo F. Assessment of response to carboplatin in patients with hormone-refractory prostate cancer: a critical analysis of drug activity. Anticancer Res 1995; 15: 2825-2828.
10. Jungi WF, Bernhard J, Hurny C et al. Effect of carboplatin on response and palliation in hormone-refractory prostate cancer. Swiss Group for Clinical Cancer Research (SAKK). Support Care Cancer 1998; 6: 462-468.
11. Steineck G, Reuter V, Kelly WK et al. Cytotoxic treatment of aggressive prostate tumors with or without neuroendocrine elements. Acta Oncol 2002; 418: 668-674.
12. Kelly WK, Curley T, Slovin S et al. Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer. J Clin Oncol 2001; 19: 44-53.
13. Urakami S, Igawa M, Kikuno N et al. Combination chemotherapy with paclitaxel, estramustine and carboplatin for hormone refractory prostate cancer. J Urol 2002; 168: 2444-2450.
14. Solit DB, Morris M, Slovin S et al. Clinical experience with intravenous estramustine phosphate, paclitaxel, and carboplatin in patients with castrate, metastatic prostate adenocarcinoma. Cancer 2003; 98: 1842-1848.
15. Oh WK, Halabi S, Kelly WK et al. A phase II study of estramustine, docetaxel, and carboplatin with granulocyte-colony-stimulating factor support in patients with hormone-refractory prostate carcinoma: Cancer and Leukemia Group B 99813. Cancer 2003; 98: 2592-2598.
16. Oh WK, Hagmann E, Manola J et al. A phase I study of estramustine, weekly docetaxel and carboplatin chemotherapy in patients with hormone-refractory prostate cancer. Clin Cancer Res 2005; 11: 284-289.
17. Berry W, Friedland D, Fleagle J et al. A phase II study of weekly paclitaxel/ estramustine/carboplatin in hormone-refractory prostate cancer. Clin Genitourin Cancer 2006; 5: 131-137.
18. Kikuno N, Urakami S, Nakamura S et al. Phase-II study of docetaxel, estramustine phosphate, and carboplatin in patients with hormone-refractory prostate cancer. Eur Urol 2007; 51: 1252-1258.
19. Bubley GJ, Carducci M, Dahut W et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 1999; 17: 3461-3467.
20. Normand SL. Meta-analysis: formulating, evaluating, combining, and reporting. Stat Med 1999; 18: 321-359.
21. Guo X, Pan W, Connett JE et al. Small-sample performance of the robust score test and its modifications in generalized estimating equations. Stat Med 2005; 24: 3479-3495.
22. Halabi S, Small EJ, Kantoff PW et al. Prognostic model for predicting survival in med with hormone-refractory metastatic prostate cancer. J Clin Oncol 2003; 21: 1232-1237.
23. Armstrong AJ, Garrett-Mayer ES, Yang Y-CO et al. A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis. Clin Cancer Res 2007; 13: 6396-6402.
24. Machiels JP, Mazzeo F, Clausse M et al. Prospective randomized study comparing docetaxel, estramustine, and prednisone with docetaxel and prednisone in metastatic hormone-refractory prostate cancer. J Clin Oncol 2008; 26: 5261-5268.
25. Sartor AO, Petrylak DP, Witjes JA et al. Satraplatin in patients with advanced hormone-refractory prostate cancer: overall survival results from the phase III satraplatin and prednisone against refractory cancer (SPARC) trial. J Clin Oncol 2008; 26 (Suppl): (Abstr 5003).
26. Armstrong A, George D. Satraplatin in the treatment of hormone-refractory metastatic prostate cancer. Ther Clin Risk Manag 2007; 3: 877-883.